window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

iPSC

  • Clinical Development,Clinical Trials,Rare Diseases,Research & Development,Technology and platforms

    PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery

    A new global initiative aims to address long-standing limitations in [...]

    April 7, 2026
  • Artificial Intelligence,Cell & Gene Therapy,Partnerships & Funding,Patient Centricity

    Cellino and Karis Bio join forces to deliver personalized cell therapy in Asia-Pacific

    Cellino and Karis Bio have announced a strategic partnership to [...]

    June 2, 2025
  • Cell & Gene Therapy,Market Access & Commercialization,Partnerships & Funding

    Cellevate consortium secures €1M Eurostars grant to boost iPSC manufacturing at scale

    April 29, 2025
  • Cell & Gene Therapy

    Cellistic unveils Echo-NK platform to scale up iPSC-based cell therapies

    April 22, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top